JP2018100276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018100276A5 JP2018100276A5 JP2018017168A JP2018017168A JP2018100276A5 JP 2018100276 A5 JP2018100276 A5 JP 2018100276A5 JP 2018017168 A JP2018017168 A JP 2018017168A JP 2018017168 A JP2018017168 A JP 2018017168A JP 2018100276 A5 JP2018100276 A5 JP 2018100276A5
- Authority
- JP
- Japan
- Prior art keywords
- methods
- novel articles
- manufacture substantially
- manufacture
- articles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681447P | 2012-08-09 | 2012-08-09 | |
| US61/681,447 | 2012-08-09 | ||
| US201261722727P | 2012-11-05 | 2012-11-05 | |
| US61/722,727 | 2012-11-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526690A Division JP6347782B2 (ja) | 2012-08-09 | 2013-08-08 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018100276A JP2018100276A (ja) | 2018-06-28 |
| JP2018100276A5 true JP2018100276A5 (enExample) | 2018-08-09 |
Family
ID=49004013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526690A Active JP6347782B2 (ja) | 2012-08-09 | 2013-08-08 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| JP2018017168A Withdrawn JP2018100276A (ja) | 2012-08-09 | 2018-02-02 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526690A Active JP6347782B2 (ja) | 2012-08-09 | 2013-08-08 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20140045843A1 (enExample) |
| EP (2) | EP2882442B1 (enExample) |
| JP (2) | JP6347782B2 (enExample) |
| KR (3) | KR102146848B1 (enExample) |
| CN (4) | CN108245518B (enExample) |
| AU (1) | AU2013299627C1 (enExample) |
| BR (1) | BR112015002285B1 (enExample) |
| CA (1) | CA2881116C (enExample) |
| CY (1) | CY1124622T1 (enExample) |
| DK (1) | DK2882442T3 (enExample) |
| EA (1) | EA029485B1 (enExample) |
| ES (1) | ES2881220T3 (enExample) |
| HR (1) | HRP20211243T1 (enExample) |
| HU (1) | HUE056127T2 (enExample) |
| IL (3) | IL288506B2 (enExample) |
| IN (1) | IN2015DN00886A (enExample) |
| LT (1) | LT2882442T (enExample) |
| MX (1) | MX367869B (enExample) |
| NI (1) | NI201500012A (enExample) |
| NZ (1) | NZ628078A (enExample) |
| PH (1) | PH12015500212A1 (enExample) |
| PL (1) | PL2882442T3 (enExample) |
| PT (1) | PT2882442T (enExample) |
| RS (1) | RS62201B1 (enExample) |
| SG (3) | SG11201500998QA (enExample) |
| SI (1) | SI2882442T1 (enExample) |
| SM (1) | SMT202100457T1 (enExample) |
| TW (2) | TWI723266B (enExample) |
| UA (1) | UA116544C2 (enExample) |
| WO (1) | WO2014025960A1 (enExample) |
| ZA (1) | ZA201500564B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| TR201903027T4 (tr) | 2010-02-11 | 2019-03-21 | Celgene Corp | Arilmetoksi izoindolin türevleri ve bunları içeren kompozisyonlar ve bunları kullanma yöntemleri. |
| SG193982A1 (en) | 2011-03-28 | 2013-11-29 | Mei Pharma Inc | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
| EP3904875B1 (en) | 2012-06-29 | 2024-11-20 | Celgene Corporation | Methods for determining drug efficacy using ikzf3 (aiolos) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| JP6306592B2 (ja) * | 2012-09-10 | 2018-04-04 | セルジーン コーポレイション | 局所進行乳癌を治療するための方法 |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| KR102299801B1 (ko) * | 2013-12-06 | 2021-09-10 | 셀진 코포레이션 | 미만성 거대 b-세포 림프종, 다발성 골수종, 및 골수암의 치료를 위한 약물 효능을 결정하는 방법 |
| US10092555B2 (en) | 2014-06-27 | 2018-10-09 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| WO2016057503A1 (en) * | 2014-10-07 | 2016-04-14 | Celgene Corporation | Use of biomarkers for predicting clinical sensitivity to cancer treatment |
| JP2018529344A (ja) * | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| CN116036278B (zh) * | 2017-05-16 | 2024-12-17 | 生物医学谷探索股份有限公司 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
| KR20240097982A (ko) | 2017-05-23 | 2024-06-27 | 메이 파마, 아이엔씨. | 병용 요법 |
| SMT202300068T1 (it) * | 2017-06-30 | 2023-03-17 | Celgene Corp | Composizioni e metodi d'uso di 2-(4-clorofenil)-n-((2-(2,6-diossopiperidin-3-il)-1-ossoisoindolin-5-il)metil)-2,2-difluoroacetammide |
| EP3651766B1 (en) | 2017-07-10 | 2024-09-11 | Celgene Corporation | 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound |
| AU2018318129A1 (en) | 2017-08-14 | 2020-03-26 | Mei Pharma, Inc. | Combination therapy |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| US11709164B2 (en) | 2017-10-26 | 2023-07-25 | National University Of Singapore | Approach for universal monitoring of minimal residual disease in acute myeloid leukemia |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3836936A4 (en) * | 2018-08-14 | 2022-05-18 | MEI Pharma, Inc. | TREATMENT OF RECURRENT FOLLICULAR LYMPHOMA |
| EP3848371A4 (en) * | 2018-09-07 | 2022-06-08 | Medshine Discovery Inc. | TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND |
| BR112021006318A2 (pt) * | 2018-10-01 | 2021-07-06 | Celgene Corp | terapia de combinação para o tratamento de câncer |
| US12263190B2 (en) * | 2018-11-08 | 2025-04-01 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
| KR102891608B1 (ko) | 2018-11-30 | 2025-11-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| KR20220006139A (ko) | 2019-04-05 | 2022-01-14 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| EA039874B1 (ru) * | 2019-06-06 | 2022-03-22 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно) |
| MX2022004686A (es) * | 2019-10-21 | 2022-05-10 | Celgene Corp | Composiciones farmaceuticas que comprenden (s)-2-(2,6-dioxopiperid in-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1- il)metil)bencil)indolin-1,3-diona y metodos de uso de las mismas. |
| BR112022007548A2 (pt) | 2019-11-07 | 2022-07-12 | Juno Therapeutics Inc | Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona |
| EP4069245A1 (en) * | 2019-12-02 | 2022-10-12 | Celgene Corporation | Therapy for the treatment of cancer |
| WO2021133920A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| IL296451A (en) | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | Mdm2 degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| BR112022026090A2 (pt) * | 2020-06-25 | 2023-01-17 | Celgene Corp | Métodos para tratar câncer com terapias de combinação |
| JP2023542930A (ja) | 2020-09-23 | 2023-10-12 | セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド | セレブロンタンパク質のモジュレータとしての置換ｎ－（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－５－イル）アリールスルホンアミド類似体 |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| MX2023009527A (es) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics Inc | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| IL312397A (en) | 2021-10-29 | 2024-06-01 | Kymera Therapeutics Inc | IRAK4 subunits and their synthesis |
| US12091411B2 (en) | 2022-01-31 | 2024-09-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2024015618A2 (en) * | 2022-07-15 | 2024-01-18 | St. Jude Children's Research Hospital, Inc. | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| TW202532072A (zh) | 2023-12-08 | 2025-08-16 | 美商西建公司 | 治療多發性骨髓瘤之療法 |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| DE60236861D1 (de) | 2001-04-26 | 2010-08-12 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| AU2005307789A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| EP2142534B1 (en) * | 2007-03-20 | 2016-08-10 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| TR201903027T4 (tr) * | 2010-02-11 | 2019-03-21 | Celgene Corp | Arilmetoksi izoindolin türevleri ve bunları içeren kompozisyonlar ve bunları kullanma yöntemleri. |
| AU2011224166B2 (en) * | 2010-03-12 | 2014-08-21 | Celgene Corporation | Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| PH12013501837A1 (en) * | 2011-03-11 | 2013-11-18 | Celgene Corp | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
-
2013
- 2013-08-08 ES ES13751007T patent/ES2881220T3/es active Active
- 2013-08-08 SM SM20210457T patent/SMT202100457T1/it unknown
- 2013-08-08 IL IL288506A patent/IL288506B2/en unknown
- 2013-08-08 CN CN201711401933.1A patent/CN108245518B/zh active Active
- 2013-08-08 CN CN202110938460.9A patent/CN114344307A/zh active Pending
- 2013-08-08 IN IN886DEN2015 patent/IN2015DN00886A/en unknown
- 2013-08-08 EP EP13751007.9A patent/EP2882442B1/en active Active
- 2013-08-08 DK DK13751007.9T patent/DK2882442T3/da active
- 2013-08-08 CA CA2881116A patent/CA2881116C/en active Active
- 2013-08-08 SI SI201331908T patent/SI2882442T1/sl unknown
- 2013-08-08 RS RS20210904A patent/RS62201B1/sr unknown
- 2013-08-08 KR KR1020157006019A patent/KR102146848B1/ko active Active
- 2013-08-08 SG SG11201500998QA patent/SG11201500998QA/en unknown
- 2013-08-08 HR HRP20211243TT patent/HRP20211243T1/hr unknown
- 2013-08-08 UA UAA201501971A patent/UA116544C2/uk unknown
- 2013-08-08 HU HUE13751007A patent/HUE056127T2/hu unknown
- 2013-08-08 KR KR1020207023283A patent/KR102266510B1/ko active Active
- 2013-08-08 PL PL13751007T patent/PL2882442T3/pl unknown
- 2013-08-08 SG SG10202108516PA patent/SG10202108516PA/en unknown
- 2013-08-08 EA EA201590345A patent/EA029485B1/ru not_active IP Right Cessation
- 2013-08-08 KR KR1020217018115A patent/KR102414005B1/ko active Active
- 2013-08-08 TW TW107117959A patent/TWI723266B/zh active
- 2013-08-08 SG SG10201701057SA patent/SG10201701057SA/en unknown
- 2013-08-08 CN CN201380052496.0A patent/CN104837491A/zh active Pending
- 2013-08-08 CN CN202110936758.6A patent/CN114366746A/zh active Pending
- 2013-08-08 PT PT137510079T patent/PT2882442T/pt unknown
- 2013-08-08 AU AU2013299627A patent/AU2013299627C1/en active Active
- 2013-08-08 NZ NZ628078A patent/NZ628078A/en unknown
- 2013-08-08 BR BR112015002285-5A patent/BR112015002285B1/pt active IP Right Grant
- 2013-08-08 WO PCT/US2013/054055 patent/WO2014025960A1/en not_active Ceased
- 2013-08-08 EP EP21177385.8A patent/EP3949968A1/en active Pending
- 2013-08-08 JP JP2015526690A patent/JP6347782B2/ja active Active
- 2013-08-08 US US13/962,776 patent/US20140045843A1/en not_active Abandoned
- 2013-08-08 LT LTEPPCT/US2013/054055T patent/LT2882442T/lt unknown
- 2013-08-08 MX MX2015001775A patent/MX367869B/es active IP Right Grant
- 2013-08-08 TW TW102128576A patent/TWI653977B/zh active
-
2015
- 2015-01-26 ZA ZA2015/00564A patent/ZA201500564B/en unknown
- 2015-01-29 IL IL237013A patent/IL237013B/en active IP Right Grant
- 2015-01-30 PH PH12015500212A patent/PH12015500212A1/en unknown
- 2015-02-06 NI NI201500012A patent/NI201500012A/es unknown
-
2016
- 2016-05-13 US US15/154,838 patent/US20160256468A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017168A patent/JP2018100276A/ja not_active Withdrawn
-
2019
- 2019-08-01 US US16/529,233 patent/US20190388429A1/en not_active Abandoned
-
2020
- 2020-07-27 IL IL276319A patent/IL276319B/en unknown
-
2021
- 2021-07-16 CY CY20211100645T patent/CY1124622T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018100276A5 (enExample) | ||
| JP2018012698A5 (enExample) | ||
| JP2023164986A5 (enExample) | ||
| JP2023113641A5 (enExample) | ||
| JP2023134519A5 (enExample) | ||
| JP2024037765A5 (enExample) | ||
| JP2020010717A5 (enExample) | ||
| JP2023113681A5 (enExample) | ||
| HUE066810T2 (hu) | Stabilizált fluorolefin kompozíciók és eljárás elõállításukra, tárolásukra és felhasználásukra | |
| JP2021502979A5 (enExample) | ||
| JP2019142968A5 (enExample) | ||
| JP2023153863A5 (enExample) | ||
| JP2014098143A5 (enExample) | ||
| WO2018081502A8 (en) | Synthetic bacteriophages and bacteriophage compositions | |
| JP2017137500A5 (enExample) | ||
| JP2018533683A5 (enExample) | ||
| JP2018064407A5 (enExample) | ||
| JP2017537928A5 (enExample) | ||
| JP2018507673A5 (enExample) | ||
| JP2020528637A5 (enExample) | ||
| JP2015186128A5 (enExample) | ||
| JP2017211493A5 (ja) | 露光装置、および、物品の製造方法 | |
| JP2023103231A5 (enExample) | ||
| JP2023139025A5 (enExample) | ||
| JP2016540026A5 (enExample) |